

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C12Q 1/56, G01N 33/86	A1	(11) International Publication Number: WO 91/02812 (43) International Publication Date: 7 March 1991 (07.03.91)
(21) International Application Number: PCT/US90/04349 (22) International Filing Date: 6 August 1990 (06.08.90) (30) Priority data: 396,234 21 August 1989 (21.08.89) US (71) Applicant: MICHIGAN STATE UNIVERSITY [US/US]; East Lansing, MI 48824 (US). (72) Inventor: HASSOUNA, Houria, I. ; 3 Lakeside Court, Grosse Pointe, MI 48230 (US). (74) Agent: McLEOD, Ian, C.; 2190 Commons Parkway, Okemos, MI 48864 (US).		(81) Designated States: AT (European patent), BE (European patent), CA, CH (European patent), DE (European patent)*, DK (European patent), ES (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent). Published <i>With international search report.</i>
(54) Title: METHOD AND ASSAY USING INACTIVATION OF FACTORS Va AND VIIIa BY PROTEIN C (57) Abstract A method and test kit for indirectly assaying for Protein C is described. The method uses tissue thrombomodulin/tissue factor (TTP) and calcium chloride to produce thrombin and activate Protein C to Protein Ca without fibrin formation and then allows time for Protein Ca to inactivate Factors V and VIII. A deficient plasma has a decreased activated thromboplastin assay clotting time compared to a control plasma. The method and test kit are used to diagnose thrombic diseases.		

BEST AVAILABLE COPY

DESIGNATIONS OF "DE"

Until further notice, any designation of "DE" in any international application whose international filing date is prior to October 3, 1990, shall have effect in the territory of the Federal Republic of Germany with the exception of the territory of the former German Democratic Republic.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MC	Monaco
AU	Australia	FI	Finland	MG	Madagascar
BB	Barbados	FR	France	ML	Mali
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GR	Greece	NL	Netherlands
BJ	Benin	HU	Hungary	NO	Norway
BR	Brazil	IT	Italy	PL	Poland
CA	Canada	JP	Japan	RO	Romania
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
DE	Germany	LU	Luxembourg	TD	Chad
DK	Denmark			TC	Togo
				US	United States of America

-1-

METHOD AND ASSAY USING INACTIVATION
OF FACTORS Va AND VIIla BY PROTEIN C

Cross-Reference to Related Application

This application is a continuation-in-part of
Serial No. 379,988, filed July 14, 1989 (MSU 4.1-59).

(1) Background of the Invention

5 The present invention relates to a method for
diagnosing thrombic disorders by determining the
inactivation of Factor V and Factor VIIla by activated
Protein C (Protein Ca) in the plasma of a patient. In
particular the present invention relates to an assay method
10 which determines whether there is a deficiency of Protein C
or whether there is increased inhibitor activity against
Protein C in the plasma of the patient.

(2) Prior Art

15 Protein C is the zymogen of a serine protease,
Protein Ca. Protein Ca exerts an anticoagulant effect in
plasma by the selective inactivation of non-enzymic
activated cofactors FVa and FVIIla. It has been shown by
several investigators that the zymogen (inactivated)
Factors V and VIII are poor substrates for Protein Ca. It
20 has also been shown that on endothelial cell surfaces in
blood, Protein C is activated to the protease by thrombin
complexed with thrombomodulin. Thrombomodulin is an
integral endothelial cell surface protein. A general
discussion of blood Factors appears in Kirk-Othmer Vol 4,
25 pages 1 to 24 (1978).

In vitro Protein C is slowly activated by
thrombin alone or by thrombin/thrombomodulin at a much
faster rate. Also Protein C is activated by purified
Factor Xa and by Akistrodon Contortrix Contortrix (Southern
30 Copperhead snake) venom. The component in the Akistrodon
venom that is selective for the activation of Protein C has
been purified and is given the trade name "PROTAC". In
addition to activating Protein C, Akistrodon Contortrix

-2-

Contortrix (ACC) venom or the purified component in relatively large amounts (500 ng 20 ul) has been found to decrease, by direct proteolysis, the procoagulant activities of purified Factors II, VII, IX, X, and to
5 cleave the A-alpha chain of fibrinogen. Thus, in vitro, ACC venom or the purified component exerts a broad substrate specificity.

Several assays to measure the biological activity of Protein C in plasma have been published. Some
10 utilize lengthy and rather complicated experimental procedures that preclude their use in clinical diagnostic laboratories. Others use the purified Protein C activator from ACC venom to measure Protein C activity as a function of the prolongation of the APTT clotting times. The
15 problem is that the zymogen (inactivated) Factors V and VIII are poor substrates for Protein C. Other assays are also described in European Patent Application Nos. 0,260,707 and 0,229,234.

Objects

20 It is therefore an object of the present invention to provide an assay method for Protein C which is accurate and reliable and a test kit for performing the method. Further, it is an object of the present invention to provide a method which is simple and economical to
25 perform and a test kit which is easy to use. These and other objects will become increasingly apparent by reference to the following description and the drawings.

In the Drawings

30 Figure 1 is a graph showing the effect of 80 ng and 500 ng of ACC snake venom on the prothrombin time (PT) assay with PNP.

Figure 2 is a graph showing PNP and shows the effect of 500 ng of ACC snake venom on various factor deficient plasmas in the PT assay. Two concentrations of
35 snake venom were tested for effect on the clotting times of PNP by PT assay. In the experiment 80 ng and 500 ng snake venom solutions in distilled water (20 ul) were added to 1

-3-

ml plasma. A prolongation of PT was observed immediately after activation of plasma with a 500 ng/20 ul solution of snake venom in distilled water. The mean clotting time of PNP of 11.2 secs was prolonged 1 1/2 times immediately
5 after adding the venom and 2 times after a 5 min incubation period.

Figures 3 and Figures 4A, 4B and 4C are graphs showing the effect of 500 ng of ACC snake venom on the PT assay on a side by side basis for various factor deficient
10 plasmas.

Figure 5 is a graph showing the effect on the APTT assay of 500 ng ACC snake venom for PNP and various Factor deficient plasmas.

Figure 6 is a graph comparing the PT and APTT
15 assays with 500 ng of ACC snake venom.

Figure 7 is a graph showing the effect on the PT and APTT assays of 500 ng of ACC snake venom on Factor X and prothrombin (Factor II).

Figure 8 is a graph showing the effect on the PT
20 and APTT assays of 80 ng of ACC snake venom on Factors II and X.

Figure 9 is a graph showing the effect of an ACC snake venom derivative on the PT and APTT assays for selected Factor deficient plasmas.

Figure 10 is a graph showing the effect on the
25 APTT assay of the ACC derivative on other factors in the APTT assay.

Figures 11 and 12 are graphs showing the results of the ACC derivative on the APTT assay.

Figure 13 is a graph showing the effect of
30 thrombin of an APTT assay on Factors V and VIII activity.

Figure 14 is a graph showing the effect on the APTT assay of 100 ng of ACC snake venom on nonactivated Factors V and VIII.

Figures 15 and 16 are graphs showing the effect
35 of 100 ng of ACC snake venom and TTP (10 ul and 20 ul)/CaCl₂ with activated PNP 10 ul and 20 ul.

-4-

Figures 17 and 18 are graphs showing the results of an APTT assay and the effect of thrombin and ACC snake venom on Factor V and VIII activity at 30 ul of TTP and 50 ul of TTP.

5 Figure 19 is a graph showing the results of an APTT assay at various concentrations of TTP/CaCl₂ and 100 ng of ACC snake venom.

Figure 20 is a graph showing a standard curve for Protein Ca activating as a function of Factors Va and
10 VIIIa inactivation.

Figure 21 is a graph showing the percent factor activity as a function of Protein C activity.

Figure 22 is a graph showing the percent Factor inactivation of Factor Va as a function of Protein C
15 activity.

Figure 23 is a graph showing the percent inactivation of Factor VIIIa as a function of Protein C activity.

General Description

20 The present invention relates to a method for diagnosing a thrombic disease by testing for inactivation of Factors Va and VIIIa by activated Protein C (Protein Ca) which comprises: activating Factor V and Factor VIII to Factor Va and Factor VIIIa and activating Protein C to
25 Protein Ca in a container of patient and pooled normal plasma (PNP) without fibrin formation in the plasmas; allowing time for Protein Ca to inactivate Factor Va and Factor VIIIa; and determining a clotting time of the patient plasma and the PNP in each container using an
30 activated thromboplastin assay (APTT).

Further, the present invention relates to a method for indirectly assaying for Protein C in blood plasma which comprises: activating Factor V and Factor VIII to Factor Va and Factor VIIIa and activating Protein C to
35 activated Protein C (Protein Ca); allowing time for Protein Ca to inactivate Factor Va and Factor VIIIa; and determining a clotting time of the patient plasma and the

-5-

PNP in each container using an activated thromboplastin time assay (APTT) of the PNP and the patient plasma in each container, wherein a particular patient plasma with a deficiency of Protein C or with increased inhibitor activity against Protein Ca has a decreased APTT compared to the APTT of PNP.

Further still the present invention relates to a method for indirectly assaying for Protein C in blood plasma by activating Factor V to Factor Va and Factor VIII to Factor VIIIa and Protein C to activated Protein C (Protein Ca) in the plasma which comprises: providing separate containers of patient plasma and pooled normal plasma (PNP); adding thrombomodulin tissue factor (TTP) and calcium chloride to the plasmas in each container so as to activate Factor V to Factor Va, Factor VIII to Factor VIIIa and Protein C to Protein Ca without fibrin formation in the plasmas; allowing time for the Protein Ca to inactivate Factor V and Factor VIII formed by the addition of TTP and calcium chloride to the plasmas; and determining a clotting time of the patient plasma and the PNP in each container using an activated thromboplastin assay (APTT), wherein a particular patient plasma with a deficiency of Protein C or increased inhibitor activity to Protein Ca has a decreased APTT compared to the APTT of PNP.

Finally the present invention relates to a kit for indirectly assaying for Protein C in blood plasma by a method which comprises providing in separate containers patient plasma and control pooled normal plasma (PNP); adding thrombomodulin/tissue factor (TTP) and calcium chloride to the plasmas in each container so as to activate Factor V to Factor Va and Factor VIII to Factor VIIIa Protein C to activated Protein C (Protein Ca) without fibrin formation in the plasmas; separately mixing Factor VIII and Factor V deficient plasma with the activated PNP and with the activated patient plasma in each of the containers; allowing time for Factor VIII and Factor V to be activated to Factor Va and Factor VIIIa and then to be

-6-

inactivated by Protein Ca in the separate containers; and determining a clotting time of the patient plasma and the PNP in each container using an activated thromboplastin time assay (APTT), wherein a patient plasma with a
5 deficiency of Protein C or with increased inhibitor activity against Protein Ca has a decreased APTT compared to the APTT of PNP which comprises: TTP with a standardized prothrombin time in PNP of between about 10 and 13 seconds to produce thrombin in a dosage amount of less than a
10 dosage amount which produces fibrin formation in the PNP and the patient plasma; Factor V and Factor VIII and Protein C deficient plasmas; and an APTT reagent.

The present invention relates to an assay for the indirect measurement of the biological activity of
15 Protein Ca by measurement of the inactivation of activated Factor V and Factor VIII in plasma. In the assay, pooled normal plasma (PNP) or patient plasma is activated by initiating thrombin formation via the extrinsic pathway. The amount of thrombomodulin tissue Factor/calcium chloride
20 used in the assay to initiate thrombin formation in PNP does not lead to fibrin generation in the activated plasma. In PNP or in patient plasma, activation by thrombin of Factor V to Factor Va and FVIII to Factor VIIIa is measured by an APTT assay with Factor V and Factor VIII deficient
25 plasmas. In the thrombin activated plasma, activation of Protein C to Protein Ca is aided by Akistrodon Contortrix Contortrix (ACC), a venom with recognized Protein C activating properties or by another Protein C activator. The amount of venom or other activator used in the assay
30 does not cause prolongation of the APTT. Care must be taken not to use too much of the activator or of the thrombomodulin tissue factor/calcium chloride.

The standard assays using relatively large amounts of ACC to determine Protein C are inherently
35 inaccurate. Studies during the development of the Protein C assay of the present invention have shown that when the amount of ACC added to 1 ml of plasma is greater than 100

ng/ml there is an immediate prolongation of the APTT, and when the amount of ACC is 500 ng/ml, there is an immediate prolongation of the PT as well as the APTT. This ACC dose dependent prolongation of the PT and APTT was examined
5 using mixtures of PNP with several factor deficient plasmas (Factors II, V, VII, VIII, X and XII). There was a generalized decrease in activity for all the factors examined. These results seem to indicate broad specificity of ACC for various Factors, and are in agreement with the
10 findings of Kiesel et al (Characterization of a Protein C Activator from Akistrodon Contortrix Contortrix Venom, J. Biol. Chem.: 262:12607-13, 1987). Another explanation for the dose dependent prolongation of the plasma clotting times with the generalized decrease in factor activities is
15 that ACC venom interferes with the activation processes on negatively charged phospholipid surfaces in the manner of a lupus-like inhibitor.

Using the same experimental approach a protein C activating protease purified from ACC (PACC), was also
20 examined for substrate specificity. When was added to plasma in the recommended dose (exactly as described by the manufacturer Diagnostica Stago) it prolonged the APTT clotting times. In a critical experiment, PACC activated plasma which was subsequently activated by Tissue
25 Factor/ CaCl_2 showed a shortening of the APTT. Factor Va and Factor VIIIa activities not only were not depleted, but were increased 11.5 fold and 29 fold over baseline. It is therefore highly likely that ACC and PACC induced prolongation of the APTT clotting times is via a lupus-like
30 inhibitor mechanism.

In the Protein C assay of the present invention, standard curves for Protein C activity were constructed in three types of Protein C deficient plasmas, a commercially prepared reagent, a Protein C immunodepleted PNP, and
35 plasma obtained from a 17 year old who attempted suicide by means of a coumarin derivative used for rat poisoning. The

-8-

source of Protein C was PNP and the choice of Protein C activator was ACC.

The most striking finding of the present invention was that as little as 20% Protein Ca activity can
5 destroy as much as 70% Factor V activity and 60% Factor VIII activity. This is in line with the work of Miletich et al (Absence of Thrombosis in subjects with Heterozygous Protein C Deficiency. NEJM 317:991-6, 1987).

When Protein Ca mediated inactivation of Factor
10 V and Factor VIII was studied in patients who were administered therapeutic doses of heparin for thrombosis related problems so that Factor V and Factor VIII activities were very low. In a very recent publication (Antithrombin III-dependent Anti-prothrombinas Activity of
15 Heparin and Heparin Fragments" Schoen P et al. J. Biol. Chem. 264:10002-7, 1989), Schoen et al hypothesize that the formation of the dissociable ternary ATIII-heparin-Factor Xa complex results in a (partial) loss of Factor Xa activity towards its natural substrate prothrombin. Thus
20 the activation of Factor V and Factor VIII is decreased in heparinized plasma as a result of a decrease in the initial rate of thrombin generation in the presence of ATIII.

Also studied was Factor V and Factor VIII activation and inactivation in the case of a 33 year old
25 patient on continuous heparin therapy for almost three years with spontaneous recurrent deep vein thrombosis (DVT) and cavenous sinus thrombosis while on heparin. In this patient, Factor Va and Factor VIIa activity remained high and was not inactivated by Protein Ca. However, Protein C
30 immunoreactive levels as well as Protein C purified from the patient's plasma were found in Dr. Miletich's laboratory to be normal. An explanation for the persistence of activated Factor V and Factor VIII in plasma and the recurrence of thrombosis while on heparin therapy
35 is explained in a recent publication. Pratt et al purified Protein C inhibitor and studied the effect of heparin on purified Protein C inhibitor interaction with proteases. A

heparin-dependent inhibition of activated Protein C was demonstrated that indicates a "procoagulant effect of heparin" mediated via Protein C inhibitor. (Protein C inhibitor: Purification and Proteinase Reactivity, Pratt C. W. et al Thrombos Res. 53: 595-602, 1989).

The mechanism for thrombosis in heparinized patients could, therefore, be the result of circulating activated Factor V and Factor VIII procoagulant activities. Under challenge to the hemostatic system such as a decrease in the blood flow, activated Factor V and Factor VIII would increase the initial rate of thrombin generation. Thus, the hypothesis of an immediate irreversible heparin-dependent inactivation of the 33 year old patient's Protein Ca could be the likely cause of his recurrent thrombotic problems that started at age 23.

An assay that measures the activation and inactivation of Factor V and Factor VIII in plasma is a sensitive indicator for hypercoagulability and reflects an imbalance of more than just the Protein C inhibitor pathway.

Poisonous Snake venom is preferred and Akistrodon Contortrix Contortrix (ACC) venom is most preferred. Purified fractions such as PACC can be used; however, they are not preferred for cost reasons. Also thrombomodulin and thrombin can be used to activate Protein C without fibrin formation; however, they are not preferred.

Specific Description

In Comparative Example I hereinafter, the major issue of substrate specificity in plasma for the ACC venom and its Protein C activating component, PACC, is addressed. Very strong evidence is presented for broad substrate specificity or lupus-like inhibitor activity.

In Example II hereinafter, the assay for Protein C is specifically described. Biological activity of Protein Ca is measured as a function of percent change in Factor V and Factor VIII activity.

-10-

A. Principle of the Protein C Assay

1. Plasma was activated to provide Factors Va, VIIIA and Ca by thrombomodulin/tissue Factor and calcium chloride. The amount of tissue Factor and calcium chloride solution that activates plasma was carefully calculated. As little as 20 ul of commercial Thromboplastin/CaCl₂ 0.02M solution activated PNP. Evidence for generation of thrombin in the activated plasma is obtained by an increase in Factor Va and Factor VIIIA activity without detectable fibrin formation. The maximum amount of Thromboplastin/CaCl₂ 0.02M solution that fully activates PNP without detectable fibrin formation is 50 ul.

To prepare a suitable commercial Thromboplastin/CaCl₂ 0.02M solution that will activate plasma at the recommended 20 ul to 50 ul range, distilled water is added to the dried powder to give in a fibrometer a clotting time by the PT assay for PNP of 11.6 seconds (\pm 0.5).

2. Measurement of Activated Factors V and VIII by the APTT assay. 30 ul plasma before activation and 30 ul plasma after activation are each added to 70 ul Factor V and Factor VIII deficient plasma. Measurement of change in activity is by the change in the clotting time by the APTT assay.

3. Protein C is preferably also activated by 80 to 100ng of ACC venom. The proteolytic activity of snake venom used, 80 to 100 ng, is selective for Protein C. The activation of Protein C by ACC venom is used to speed the activation process that is started by thrombin. Thrombin formation is initiated in plasma by thromboplastin/calcium chloride solution as described above. If the snake venom step is omitted, a time interval of one hour is necessary for the inactivation of Factors Va and Factors VIIIA by thrombin activated Protein Ca.

B. Biological Activity of Protein Ca is measured as a function of percent change in Factor V and Factor VIII activity. At the end of one hour incubation,

-11-

30 ul of plasma mixture are added to 70ul of Factor V and Factor VIII deficient plasma. Factor activity is determined from clotting times by means of standard curves. Protein C activity is calculated from the change in Factor Va and Factor VIIa activity.

MATERIALS AND REAGENTS

Preparation of Pooled Normal Plasma (PNP)

Human pooled normal plasma (PNP) was prepared from forty healthy blood donors ranging in age from 18 to 64 years. Blood (4.5 ml) was drawn from each donor into vacutainer tubes each containing 0.5 ml of 3.85% acidified sodium citrate solution. Blood was spun at 2,000 r.p.m. in a refrigerated Beckman table top centrifuge at 2°C for 10 to 15 minutes. The platelet poor plasma was pooled into a polystyrene beaker placed on ice, and then assayed for procoagulant factor levels by the PT and APTT assays. Fibrinogen levels were determined by clotting and chemical assays. One milliliter aliquots of PNP were then pipetted into 4ml polystyrene capped tubes and stored at -80°C for use in the Protein C experiments.

Akistrodon Contortrix Contortrix (Southern Copperhead Snake; ACC) Venom

One gram of freeze dried ACC venom powder was purchased from Sigma Chemical Company of St. Louis, MO. Twenty samples of dried powder of 0.1 mg each were weighed and stored in 15 ml graduated capped plastic centrifuge tubes at 4°C until further use. The dried venom was dissolved in distilled water (0.1 mg/10 ml) and assayed for stability by adding 500ng ACC venom to 1 ml PNP. The proteolytic anticoagulant activity was tested by the APTT assay. The proteolytic anticoagulant activity was markedly decreased within 24 hours after reconstitution in distilled water. Proteolytic anticoagulant activity was, though, retained in the dried powder. Fresh solutions therefore were prepared daily by adding 10 ml distilled water to the graduated plastic centrifuge tubes containing 0.1 mg of

-12-

dried powder. Venom solutions were kept on ice for the duration of the experiments.

Two concentrations of the venom, 80ng and 500ng per milliliter PNP, were tested for substrate selectivity by PT, APTT and Thrombin Clotting Time (TCT) assays.

Tissue Thromboplastin Reagents

Two reagents from the same manufacturer were used. The Tissue Thromboplastin/Calcium Chloride Powder (TTP/CaCl₂) was purchased from Ortho Diagnostic Systems Inc., Raritan, N.J. The Ortho Brain thromboplastin ISI Standard lot 871007 was obtained from Ortho Diagnostics Systems.

The commercially prepared tissue thromboplastin/calcium chloride powder was reconstituted to give a prothrombin time on a fibrometer of 11.6 ± 0.5 seconds on 100ul PNP. These reagents have high thrombomodulin activity (Thrombos Res 43:265-274 (1986)).

Activated Partial Thromboplastin (APTT) Reagent

Thrombosil™ I, a commercially prepared brain cephalin with silica activator, was purchased from Ortho Diagnostic Systems.

Calcium Chloride Reagent - 0.02 molar solution

Thrombofax™, a bovine brain cephalin solution was also purchased from Ortho Diagnostic Systems.

Human Alpha Thrombin with a specific activity of 3,000 units/ug was obtained from an independent source. Clotting activity of the thrombin in 0.1 M CaCl₂ solutions is retained for several years. A preservative, Thimerosal™, purchased from Sigma Chemical Company, is added to the thrombin solutions at 1 mg/100,000 ml. Thrombin solutions of 1.5 to 1.2 unit per 100ul 0.1 M CaCl₂ were prepared to give a clotting time of 8-10 seconds with 200ul PNP.

Equipment

A Dataclot™ 2 fibrometer from Helena Laboratoriales, Beaumont, Texas was used for the clotting

-13-

experiments. An Apple™ MacIntosh Computer and an IBM™ PC were used for the analysis and graphing of the data.

EXPERIMENTAL PROCEDURES

Prothrombin Time (PT) Assay

5 PNP or plasma mixtures (100ul) were clotted with 200ul TTP/CaCl₂ solution. The clotting times were recorded on a fibrometer.

Activated Partial Thromboplastin Time (APTT) Assay

10 PNP or plasma mixtures (100ul) were incubated with APTT reagent for 3 to 5 minutes then clotted with 100ul CaCl₂ 0.02 M.

Thrombin Clotting Time (TCT) Assay

200ul PNP or plasma mixtures were clotted with 100ul thrombin solution (1.5 to 1.2 unit)

15 Single Factor Genetically Deficient Plasma Reagents (less than 1% activity)

Factor XI deficient reagent was purchased from George King, Biomedical, Inc., Overland Park, KS. All other factor deficient plasmas were obtained by
20 plasmapheresis from patients at the Michigan State University Medical Center.

Standard Curves for Factors V, VII, VIII, IX, X, XI, and XII

25 Standard curves were constructed using single factor genetically deficient plasmas and PNP. The clotting times by PT and APTT assays for about forty estimates per point were analyzed. Standard deviation, linear regression, Pearson's correlation coefficient, as well as mean and median were calculated for each curve.

30 In Table I the clotting times by PT for Factors V, VII and X activities ranging from 80% to less than 1% are presented.

-14-

TABLE I

Standard curves for descending ranges of Factors V, VII and X activities and the mean clotting times obtained by PT assay.

5 A least squares linear regression of the actual data points from the straight lines of the best fit are shown in this figure. Factor activities and the corresponding clotting times that represent the critical threshold procoagulant Factor V, VII or X levels whereby spontaneous bleeding can occur are placed in boxes.

10 Comparison of Data for the Mean Clotting Times by the PT Assay for Descending Ranges of Factors V, VII, and X Procoagulant Activities (40% to less than 1%)

	% Factor Activity	(Clotting Time in Seconds)		
		FV	FVII	FX
15	40	13.08	12.78	12.81
	35	13.66	12.97	13.29
	30	14.25	12.16	13.77
	25	14.83	13.35	14.26
20	20	15.54	13.89	15.09
	16	16.78	14.71	16.61
	15	17.09	14.92	16.98
	12	18.02	15.54	18.12
	8	19.25	16.36	19.63
25	4	20.49	17.19	21.14
	3	25.13	18.43	26.13
	2	31.55	20.79	32.51
	1.5	34.76	22.02	35.69
	1	37.97	23.25	38.88
30	0.5	41.18	24.47	42.07
	0	44.39	25.70	45.26

In Table II the data presented are the clotting times by the APTT assay for Factors V, VIII, IX, X, and XI activities ranging from 80% to less than 1%.

35

-15-

TABLE II

Standard curves for descending ranges of Factors V, VIII, IX, X and XI activities and the mean clotting times obtained by the APTT assay.

5 A least squares linear regression of the actual data points from the straight lines of the best fit are shown in this figure. Factor activities and the corresponding clotting times that represent the critical threshold procoagulant Factor V, VIII, IX, X or XI activities whereby spontaneous.

10 Comparison of Data for the Mean Clotting Times by the APTT Assay for Descending Ranges of Factors V, VIII, IX and XI Procoagulant Activities (40% to less than 1%)

	% Factor Activity	FV	FVIII	FIX	FX	FXI
15						
						Clotting Time in Seconds
	40	30.38	28.97	30.12	31.53	33.80
	35	31.73	30.16	30.61	32.18	34.77
	30	33.08	31.35	21.10	32.83	35.73
	25	34.43	32.54	31.58	33.48	36.68
20	20	35.78	33.73	32.06		37.63
	16	36.86	34.69			
	16	37.1	33.74	33.56	36.34	
	12	42.4	37.97	35.93	39.13	
	8	47.7	42.20	38.30	41.91	44.59
25	4	53.0	46.42	40.67	44.70	53.29
	2		48.54			57.65
	2	65.75	47.54	45.11	47.42	
	1.5	77.44	55.61	47.76	52.32	70.95
	1	89.14	63.68	50.40	57.23	
30	0.5	100.84	71.75	53.04	62.13	88.51
	0	112.54	79.82	78.54	67.03	97.29

Factor Assays:

35 In the Protein C assay experiments, most of the Factor assays were performed by PT or APTT assay after adding 30ul plasma mixtures to 70ul single factor deficient plasma (Factors V, VII, VIII, IX, X, XI or XII) and recording the mean clotting times. The mean clotting time was never from less than four estimates with an average of ten estimates per point. Factor activities were then

-16-

derived from the corresponding clotting times on the linear regression of the standard curves.

Activation of Plasma

One milliliter of PNP or patient plasma was
5 activated by adding 50ul, 30ul, 20ul or 10ul solutions of
TTP/CaCl₂. The tube was gently shaken and incubated at
37°C for times ranging from zero to one hour. PT, APTT,
TCT, and Factor assays were performed on activated plasma
and on plasma prior to activation.

10 Standard Curves for Protein C

Three standard curves for Protein C were
constructed on:

- 1) Protein C freeze dried deficient plasma
reagent purchased from Diagnostica Stago, Asniere, France.
- 15 2) Plasma obtained from a 16 year-old patient
who attempted to commit suicide by ingestion of three
packages of a long lasting coumarin derivative prepared
commercially and for use as a rat poison (trade name:
Enforce™). The patient's PT was 72 secs. (control 11.2
20 secs.), APTT 132.4 secs. (control 26.4 secs), and TCT 9.9
secs. (control 9.2 secs.). Factor VII activity in this
patient's plasma was less than 1%, Factor X activity 2%,
and FIX activity 2.5%.

3. PNP immunodepleted of Protein C by
25 anti-Protein C insolubilized rabbit immunoglobulins.

Human anti Protein C antibodies were purchased
from Diagnostica Stago, Asnieres, France. Coupling of the
anti-Protein C antibodies to sepharose beads and
immunodepletion of PNP by insolubilized antibodies was
30 performed as described by H. I. Hassouna and J. A. Penner.
Antibody Techniques and Blood Coagulation. Sem Thromb
Haemost (E. F. Mammen, ed) Vol 7, No 2, pp 61-111, (1981).

-17-

COMPARATIVE EXAMPLE I

Substrate Specificity for Akistrodon Contortrix
Contortrix venom (ACC) and Its Purified Protein C
Activating Protease "PROTAC"

5 Two concentrations of Akistrodon Contortrix
Contortrix (ACC) venom were tested for effect on the
clotting times of PNP by PT assay. In the experiment 80ng
and 500ng ACC venom solutions in distilled water (20ul)
were added to 1 ml plasma. A prolongation of the PT was
10 observed immediately after activation of plasma with
500ng/20ul ACC venom in distilled water. The mean clotting
time of PNP (11.2 secs) was prolonged 1 1/2 times
immediately after adding the venom and 2 times after a 5
minute incubation period as shown in Figure 1. No effect
15 was observed when 80ng ACC venom was added to plasma even
after an incubation period greater than 5 minutes at 37°C
(Figure 1).

To determine what effect the proteolytic
activity of the ACC venom (500ng) had on coagulation
20 factors in plasma, 30ul of plasma activated by ACC venom
was added to 70ul of factor deficient plasma (Factors V,
VII, VIII, and XII). No change in clotting times was
observed with Factor VIII or Factor XII deficient plasmas
after activation with the venom. A prolongation of the PT
25 was seen with Factor V and Factor VII deficient plasmas
(Figure 2). In Figures 3 and 4, the effect of 500ng ACC
venom on the clotting times of PNP by the PT assay is
compared side by side with the effect of 500ng ACC venom on
selected factors (these findings were presented separately
30 in Figure 1 and Figure 2). As can be seen in Figure 5, the
effect of 500ng ACC venom on PNP and on coagulation Factors
V, VII, VIII, and XII by APTT is more pronounced and
nonselective. In Figure 6, the effect of 500ng ACC venom
on PNP and Factors V, VII, VIII, and XII by the PT and APTT
35 assays is presented for comparison.

To determine whether the proteolytic activity of
the venom is directed at Factor X and prothrombin, the same

-18-

experimental protocol using Factor II and Factor X deficient plasmas was performed. As can be seen in Figure 7, there is a marked prolongation of the APTT in Factor X deficient plasma indicating possible inactivation of Factor X by the venom. A time dependent inactivation of prothrombin is observed, though it is modest compared to the substantial decrease in Factor X activity. When the amount of ACC venom used was 80ng, there was no apparent inactivation of any of the coagulation factors examined (Figure 8). From these results, it appears likely that, at the concentration of 500ng ACC venom per ml PNP used in the experiments, the proteolytic specificity of the venom is broad. This is in agreement with previously published work by Keisel, et al (Characterization of a Protein C Activator from Akistrodon Contortrix Contortrix Venom, J. Bio. Chem., 262 p. 12607-13, (1987)).

Another possibility, even more probable, is that in plasma, ACC venom interferes with the activation processes on negatively charged phospholipid surfaces and behaves in the manner of a lupus-like inhibitor. Regardless of the mode of action of the venom, whether by direct proteolysis or by preventing complex assembly on negatively charged phospholipids, it is obvious that at the 50 ng concentration of ACC venom used in the experiments, the prolongation of the APTT is not by Protein Ca mediated inactivation of Factors VA and VIIIA and thus the prior art assays are not measuring Protein C.

To examine the substrate specificity of PACC, it was added to PNP in the same enzyme or substrate ratio as recommended by the manufacturer. PNP (1 ml) was added to 1 vial of PACC. 30ul of the plasma mixture was immediately tested by APTT in 70ul each of Factor V, VIII, X, and XII deficient plasma. A decrease in Factor V activity from 16-20% to 3% was observed. For Factor VIII, a very similar decrease in activity from 16-20% to 1% was obtained; Factor X activity decreased from 20-25% to 1% and FXII activity from 40 to 4% (Figure 9). In Figure 10, the

-19-

results of the activity measurements for Factors V, VIII, X and XII by PAC are expressed as fold changes in activity from initial factor activity measured in 30ul PNP.

It appears from these results that PACC shares
5 broad substrate specificity with the protease of the venom ACC of the Akistrodon Contortrix Contortrix. To test whether PACC induced prolongation of the APTT clotting times and the apparent inactivation of Factors V, VIII, X and XII was a result of direct proteolysis of the
10 procoagulant plasma factors or a "lupus inhibitor-like" effect on plasma, a critical experiment was performed. One milliliter of PNP was added to dried PAC exactly as performed in the previous experiment and an APTT was immediately performed. The clotting time was greater than
15 200 seconds. Factor V and Factor VIII activities were 3% and 1% respectively. These findings correlated with the previous ones shown in Figures 9 and 10. The PNP/PAC mixture was then activated with 50ul TTP/CaCl₂ mixture. As can be seen in Figure 11, Factor V and Factor VIII
20 activities measured, as previously described, were found to increase in a time dependent manner over 15 minutes incubation. In Figure 12, the results are expressed as a change in activity (fold difference) for Factors V and VIII. It appears very likely therefore that at the enzyme to
25 substrate ratio as recommended by the manufacturer, the effect of PACC on the clotting time of PNP is a "lupus inhibitor-like effect", and not a Protein Ca mediated inactivation of native Factors Va and VIIla.

EXAMPLE 2

30 Protein C Assay. Measurement of the biological activity of Protein Ca as a function of percent change in Factor V and Factor VIII activity
A. Determination of Optimal conditions associated with activation and inactivation of Factors V and Factor VIII in
35 plasma.

-20-

Several experiments were performed to determine the time course activation and inactivation of Factor V and Factor VIII in plasma.

1. Time course of thrombin mediated activation of Factor V and Factor VIII by addition of TTP/CaCl₂ to 1 ml PNP. In Figure 13, the results of an experiment in which 20ul of a 0.02M mixture of TTP/CaCl₂ was added to 1 ml PNP are presented. Factor V and Factor VIII activity were measured immediately following activation (zero time), then at five minutes, 20 minutes, and one hour. As can be seen, a six fold increase in Factor V activity and a nine fold increase in Factor VIII activity occurred immediately following activation. There was a further rise in Factor VIII activity (12 fold increase from initial activity) at the end of five minutes, while Factor V activity remained constant at six fold increase above baseline activity. At the end of one hour an almost complete inactivation of the activated Factor V and activated FVIII had occurred.

2. Time course effect of 100ng ACC venom on Factor V and Factor VIII activity.

The effect of 100ng ACC venom on nonactivated Factor V and Factor VIII was examined in 1 ml plasma. A very mild decrease in Factor V activity at zero time from 20% to 12% (-0.4 fold) was followed by a slight rise to baseline activity (16-20%) at five minutes and a further drop to 12% (-0.4 fold) which continued until the end of the experiment (Fig. 14). There was no rise in Factor VIII activity at five minutes. The decrease in Factor VIII activity at zero time from 15 to 2.5% (-0.9 fold) was twice that of Factor V and the apparent loss in activity was maintained over the one hour duration of the experiment.

3. Time course effect of thrombin and Protein Ca mediated activation and inactivation of Factors V and VIII.

Fixed amounts of ACC venom (100ng) and varying amounts of TTP/CaCl₂ were used to identify optimum

-21-

activation and inactivation conditions for the thrombin/Protein Ca mediated process. In four experiments 1 ml PNP was activated first by TTP/CaCl₂ and, immediately following, ACC venom (100ng) was added. Factor V and
5 Factor VIII activities were measured in genetically deficient Factor V and FVIII plasmas as described in the materials and methods.

The effect of TTP/CaCl₂ (10ul and 20ul) on Factor V and Factor VIII activation and inactivation in the
10 presence of ACC venom was not significant. This is demonstrated in Figures 15 and 16.

The effect of TTP/CaCl₂ (30ul and 50ul) can be seen in Figures 17 and 18. There is an immediate three fold increase in Factor V activity and a four fold increase
15 in Factor VIII activity. After five minutes Factor VIII activity is almost gone while Factor V activity remains constant. At 20 minutes Factor V and Factor VIII activities have reached preactivation levels.

A graph comparing results from all the
20 experiments is presented in Figure 19. Optimal activation and inactivation of Factor V and Factor VIII appears to be associated with 50ul TTP/CaCl₂ and 100ng Akistrodon Contortrix Contortrix venom.

B. Standard Curves for Protein C Activity

25 The source of Protein C was PNP in concentrations of 20% (600ul), 40% (1.2 ml), 50% (1.5 ml), 66.7% (2 ml), 73.3% (2.2 ml), and 80% (2.7 ml) added to Protein C deficient plasma to achieve a total volume of 3 ml.

30 Three types of Protein C deficient plasmas were used to construct the standard curves.

1. Protein C deficient freeze dried plasma reagent purchased from Diagnostica Stago, Asnieres, France.

2. PNP immunodepleted by insolubilized
35 anti-Protein C antibodies raised in rabbits (as described in materials and methods)

-22-

3. Plasma obtained from a patient poisoned with a coumarin derivative used to exterminate rodents.

The Protein C assay was performed as follows: to the 1 ml plasma mixtures (deficient plasma and PNP) was added TTP/CaCl₂ (30ul) and ACC venom (100ng). Factor V and Factor VIII measurements before activation, after activation with TTP/CaCl₂ and after incubation with TTP/CaCl₂ and ACC venom for 30 minutes were performed as previously described.

The clotting times by PT and APTT for the three types of Protein C deficient plasmas are presented in Table III.

TABLE III

Protein C Deficient Plasma	PT	APTT
	CT (sec.) Cont.= 11.2	CT (sec.) Cont. = 26.4
Diagnostica Stago	16.5	57.1
Immunodepleted	12.8	33.9
Coumarinized	72.0	132.4

Factor V and Factor VIII activity levels were determined in all three deficient plasma types before activation, after activation with TTP/CaCl₂, and after activation with TTP/CaCl₂ and ACC venom. The results are presented in Table IV.

-23-

TABLE IV

Protein C Deficient Plasma Type	Before Activation		After Activation TTP/CaCl ₂ (30 µl)		After Activation TTP/CaCl ₂ (30 µl) ACC (100 ng) 30 mins. Incubation	
	Activity FV	Activity FVIII	Activity FV	Activity FVIII	Activity FV	Activity FVIII
10 Diagnostica Stago	4%	4%	100%	100%	100%	100%
Immunodepleted	16-20%	16-20%	100%	100%	100%	100%
Coumarinized	8%	2%	24%	80%	14% (10% decrease)	8% (72% decrease)

15 As can be seen from the results, there is no detectable Protein Ca mediated inactivation of Factor Va or Factor VIIIIa in the Protein C deficient plasmas from Diagnostica Stago and the immunodepleted plasma. In the coumarinized plasma a substantial decrease in Factor 20 VIII activity from 70% to 8% is observed while the decrease in Factor V activity is more modest from 24% down to 14%. The modest drop in Factor V activity as compared to the substantial decrease in Factor VIII activity could be attributed to the effect of the coumarin derivative on a 25 post translational vitamin K-dependent process necessary for the biological activity of Protein S as well as Protein C. Protein S has been shown to have an independent role in the regulation of Protein Ca mediated inactivation of Factor Va.

30 To construct standard curves, Protein deficient plasma/PNP mixtures (1 ml) were activated with TTP/CaCl₂ (30ul) and ACC venom (100ng). At the end of 30 minutes incubation at 37°C, the plasma mixtures (30ul) were added to 70ul of Factor V or Factor VIII deficient plasma and 35 APTT assays were performed as described in the materials and methods section. The patterns of inactivation for Factor V and for Factor VIII by Protein Ca were identical in Diagnostica Stago Protein C deficient plasma or

-24-

immunodepleted plasma. These results are seen in Table V and are graphically represented in Figure 20.

TABLE V

5 Inactivation of Factor Va and Factor VIIa
by Protein Ca - Standard Curve of
Actual Data Points

Factor Va		Factor VIIa	
Protein C Activity	FVa Inactivated	Protein C Activity	FVIIa Inactivated
10 20-40%	70%	20%	60%
50-66.7%	88%	40-66.7%	80%
73.3-80%	92%	73%	92%
	Slope = .417 r = .9029 Y int. = 60.38	80%	98.5%
15			Slope = .540 r = .925 Y int. = 51.8

In Table V and VII the percent inactivation of Factor Va and Factor VIIa activities by Protein Ca were derived from the straight lines of the best fit of the actual data points.

TABLE VI

25 Inactivation of Factor Va and Factor VIIa
by Protein Ca - Standard Curve of Inactivation
Derived From the Straight Lines of Best Fit

Factor Va		Factor VIIa	
Protein C Activity	FVa Inactivated	Protein C Activity	FVIIa Inactivated
30 20%	68.7%	20%	62.7%
40%	77%	40%	73.5%
50%	81.2%	50%	78.9%
66.7%	88.2%	66.7%	87.9%
73.3%	90.9%	73.3%	91.5%
80%	93.8%	80%	95.1%

35 From) Slope = .417 From) Slope = .540
Actual) r = .9029 Actual) r = .925
Data Points) Y int. = 60.38 Data Points) Y int. = 51.8

-25-

TABLE VII
Protein Ca Mediated Inactivation of
Factor Va and Factor VIIa

	<u>Protein C Activity</u>	<u>FVa Inactivated</u>	<u>FVIIa Inactivated</u>
5	20%	68.67%	62.66%
	30%	72.85%	68.0%
	40%	77.0%	73.48%
	50%	81.20%	78.80%
	60%	85.38%	84.30%
10	65%	87.41%	86.99%
	70%	89.56%	89.70%
	75%	91.65%	92.40%
	80%	93.74%	95.10%
	85%	95.83%	97.80%
15	90%	97.90%	100%
	95%	100%	

A standard curve showing actual data points and the line of the best fit are expressed graphically in Figure 20 for Factor Va inactivation and in Figure 21 for Factor VIIa inactivation by Protein Ca.

The residual Factor Va and Factor VIIa activity as a function of the Protein Ca mediated inactivation process are shown in Figures 22 and 23.

Two computer derived compilations of the possible permutations for Factor V activity (Table VIII) and Factor VII activity (Table IX) as a function of the clotting times by the APTT assay were developed to aid in the determination of Protein Ca mediated inactivation of Factor Va and Factor VIIa.

-26-

TABLE VIII
FACTOR V - ACTIVITY

	APTT (secs.)	%FV activity	APTT (secs.) after act. SD+	FV activity after activation	Δacti- vity	fold change
5	34± secs.	20 to 25%	26 30 34	100% 40% 20-25%	75-80% 15-20% 0%	3.75-3 2.6-1.6 0
10	37± secs.	16 to 20%	26 30 34	100% 40% 25%	80% 20% 19-5%	4 2.5-2 1.6-1.25
15	42 to 47 secs.	8 to 12%	26 30 34 37 42	100% 40% 25% 16-20% 8-12%	88% 28% 13% 4-8% 0%	7.5 3.5 2 0.16 0
20	53 secs.	4%	26 30 34 37 42 53	100% 40% 25% 16-20% 8-12% 4%	96% 36% 21% 12-16% 4-8% 0	24 10 6.25 4-5 2-3 0
25	65 to 90 secs.	1 to 2%	26 30 34 37 42 53 65-90	100% 40% 25% 16-20% 8-12% 4% 1-2%	98-99% 38-39% 23-24% 15-19% 7-11% 2-3% 0	50-100 19-40 12-24 10-20 4-6 2-4 0

-27-

TABLE IX
FACTOR VIII - ACTIVITY

	APTT (secs.)	FVIII activity	APTT (secs.) after act. SD+	FVIII activity after activation	Δ acti- vity	fold change
5			26	100%	75-80%	3.75-3
	33 \pm 1 secs.	20 to 25%	30	40%	15-20%	2.6-1.6
			34	20-25%	0%	0
10	37 secs.	12%	26	100%	88%	7
			30	40%	28%	3.4
			34	25%	8-12%	1.6-2
			37	12%	0	0
15	42 secs.	8%	26	100%	92%	12.5
			30	40%	32%	5
			34	25%	12-17%	2.5-3
			37	12%	4%	1.5
			42	8%	0	0
20	46 to 48 secs.	2 to 4%	26	100%	98-96%	49-24
			30	40%	38-36%	19-9.5
			34	25%	18-21%	9-5
			37	12%	10-8%	5-2
			42	8%	6-4%	3-0
			46-48	4%	0	0
25	55 to 80 secs.	1.5 to less than 1%	26	100%	98.5%	65
			30	40%	38.5%	25
			34	25%	18.5-23.5%	12-16
			37	12%	10.5%	7
			42	8%	6.5%	4.3
30			46-48	2-4%	0.5-2.5%	2
			55-80	1.5-<1%	0	0

Data is presented for Factor V and Factor VIII before activation, and after the thrombin introduced change in native Factor V to Factor Va and in native Factor VIII to Factor VIIIa. As mentioned earlier, thrombin is generated in plasma by adding small quantities of TTP/CaCl₂ (20ul, 30ul, 50ul) that are not sufficient to induce fibrin formation, but enough to cause several fold enhancement of Factor V and Factor VIII activity. The percent change in activity at each level and the fold change in activity from non-activated to activated state are also shown in the Tables. The changes in Factor V and Factor VIII activity have been calculated for plasma levels of these factors ranging from 25% to less than 1%. This makes possible the use of the tables with a wide

SUBSTITUTE SHEET

-28-

range of plasma types from healthy or diseased individuals. Oral anticoagulant therapy does not cause decreases in Factor V or Factor VIII activities in plasma, however, generation of thrombin by TTP/CaCl₂ in plasmas from coumadinized
5 individuals is a function of the levels of biologically active Factors VII, IX, X and prothrombin. In heavily coumadinized plasmas very little thrombin is generated and thus activation of Factor V and Factor VIII is incomplete. Similarly in liver disease and even in aged plasma or in the
10 presence of a lupus inhibitor the activation process is more subtle than in PNP. This may also be true for hypercoagulable disease and DIC.

Thus, by the use of Tables VIII and IX it is possible to determine the Protein C mediated decrease in
15 Factor Va and Factor VIIIa activity that indirectly reflects Protein C biological activity.

As can be seen from the standard curves and from the coumarinized patient's plasma, very little Protein C (20%) is needed to inactivate about 2/3 of activated Factor
20 Va (70%) and Factor VIIIa (60%).

Protein C mediated inactivation of Factor V and Factor VIII was examined in plasmas from several patients administered therapeutic doses of heparin for thrombosis related problems. These results can be seen in Table
25 X.

TABLE X
Effect of Heparin Therapy
on Factor V and Factor VIII activity

Patient 5 Name	Factor V Activity			Factor VIII Activity		
	Before Activation (Control: 20%)	After Acti- vation (Control: 100%)	Snake Venom (Control: 1-20%)	Before Activa- tion (Control: 20%)	After Activation (Control: 10%)	Snake Venom (Control: 1-20%)
10 N.M.	3%	8%	2%	4%	10%	1.5%
S.T.	5%	14%	5%	10%	100%	25%
N.W.	1.5%	15%	1.5%	2%	12%	1%
S.B.	1.5%	2%	1.5%	1.5%	2%	1.5%
K.D.	2%	16%	2%	1.5%	30%	2%

15 In a very recent publication (Antithrombin
III-dependent Antiproteolytic Activity of Heparin and
Heparin Fragments", Schoen, P., et al., J. Biol Chem
264:100002-7, 1989). Schoen et al hypothesize that the
formation of the dissociable ternary ATIII-heparin-Factor
20 Xa complex results in a (partial) loss of Factor Xa
activity towards its natural substrate, prothrombin. Thus,
the activation of Factor V and Factor VIII is decreased in
heparinized plasma as a result of a decrease in the initial
rate of thrombin generation in the presence of ATIII.

25 Also studied was Factor Va and Factor VIIIa
inactivation in the case of a 33 year old patient on
continuous heparin therapy for almost three years with
spontaneous recurrent DVT and cavernous sinus thrombosis
while on heparin. In this patient, Factor V and Factor
30 VIII activity remained high and was not inactivated by
Protein C. However, Protein C immunoreactive levels as
well as Protein C purified from the patient's plasma were
found in Dr. Miletich's laboratory to be normal. An
explanation for the persistence of activated Factor V and
35 Factor VIII in plasma and the recurrence of thrombosis
while on heparin therapy is explained in a recent

-30-

publication. Pratt et al purified Protein C inhibitor and studied the effect of heparin on purified Protein C inhibitor interaction with proteases. A heparin-dependent inhibition of activated Protein C was demonstrated that indicates a "procoagulant effect of heparin" mediated via Protein C inhibitor (Protein C Inhibitor: Purification and Proteinase Reactivity, Pratt, C. W., et al., Thrombos Res 53: 595-602, (1989)).

The mechanism for thrombosis in heparinized patients could, therefore, be the result of circulating activated Factor V and Factor VIII procoagulant activities. Under challenge to the hemostatic system, such as a decrease in the blood flow, activated Factor V and Factor VIII would increase the initial rate of thrombin generation. Thus, the hypothesis of an immediate irreversible heparin-dependent inactivation of the 33 year old patient's Protein Ca could be the likely cause of his recurrent thrombotic problems that started at age 23. This hypothesis remains to be confirmed.

An assay that measures the activation and inactivation of Factor V and Factor VIII in plasma is a sensitive indicator for hypercoagulability and reflects an imbalance of more than just the Protein C inhibitor pathway.

It is intended that the foregoing description be only illustrative of the present invention and that the present invention be limited only by the hereinafter appended claims.

30

-31-

I CLAIM:

-1-

A method for diagnosing a thrombic disease by testing for inactivation of Factors Va and VIIIA by activated Protein C (Protein Ca) which comprises:

- 5 (a) activating Factor V and Factor VIII to Factor Va and Factor VIIIA and activating Protein C to Protein Ca in a container of patient and pooled normal plasma (PNP) without fibrin formation in the plasmas;
- (b) allowing time for Protein Ca to inactivate Factor Va and Factor VIIIA; and
- 10 (c) determining a clotting time of the patient plasma and the PNP in each container using an activated thromboplastin assay (APTT).

-2-

A method for indirectly assaying for Protein C in blood plasma which comprises:

- 5 (a) activating Factor V and Factor VIII to Factor Va and Factor VIIIA and activating Protein C to activated Protein C (Protein Ca);
- (b) allowing time for Protein Ca to inactivate Factor Va and Factor VIIIA; and
- 10 (c) determining a clotting time of the patient plasma and the PNP in each container using an activated thromboplastin time assay (APTT) of the PNP and the patient plasma in each container, wherein a particular patient plasma with a deficiency of protein C or with increased inhibitor activity against Protein Ca has a decreased APTT compared to the APTT of PNP.

15

-3-

The method of Claim 2 wherein a Protein C activation accelerator is added to the plasmas in step (a).

-32-

-4-

A method for indirectly assaying for Protein C in blood plasma which comprises:

- 5 (a) activating Factor V and Factor VIII to Factor Va and Factor VIIa and activating Protein C to activated Protein C (Protein Ca) in a container of a pooled normal plasma (PNP) and of a patient plasma without fibrin formation in the plasmas; and
- 10 (b) measuring inactivation of Factor V and Factor VIII for Protein Ca in the patient plasma and in the PNP by an activated partial thromboplastin time assay (APPT).

-5-

The method of Claim 4 wherein the activation of Protein C to Protein Ca is accelerated by an activation accelerator.

-33-

-6-

A method for indirectly assaying for Protein C in blood plasma by activating Factor V to Factor Va and Factor VIII to Factor VIIIa and Protein C to activated Protein C (Protein Ca) in the plasma which comprises:

- 5 (a) providing separate containers of patient plasma and pooled normal plasma (PNP);
- (b) adding thrombomodulin tissue factor (TTP) and calcium chloride to the plasmas in each container so as to activate Factor V to Factor Va, Factor VIII to Factor VIIIa and Protein C to Protein Ca without fibrin formation
- 10 in the plasmas;
- (c) allowing time for the Protein Ca to inactivate Factor V and Factor VIII formed by the addition of TTP and calcium chloride to the plasmas; and
- 15 (d) determining a clotting time of the patient plasma and the PNP in each container using an activated thromboplastin assay (APTT), wherein a particular patient plasma with a deficiency of Protein C or increased inhibitor activity to Protein Ca has a decreased APTT
- 20 compared to the APTT of PNP.

-7-

The method of Claim 6 wherein a Protein C activation accelerator is added to the plasmas in each container in step (b).

-34-

-8-

A method for indirectly assaying for Protein C by activating Factor V to Factor Va and Factor VIII to Factor VIIla the Protein C to Protein Ca in blood plasma which comprises:

- 5 (a) providing in separate containers patient plasma and control pooled normal plasma (PNP);
- (b) adding thrombomodulin tissue factor (TTP) and calcium chloride to the plasmas in each container so as to activate Factor V to Factor Va and Factor VIII to
- 10 Factor VIIla Protein C to Protein Ca without fibrin formation in the plasmas;
- (c) separately mixing Factor VIII and Factor V deficient plasma with an aliquot the PNP and with an aliquot of the patient plasma from each of the containers;
- 15 (d) allowing time for Factor V and Factor VIII to be activated to Factor Va and Factor VIIla and then to be inactivated by Protein Ca in the separate containers; and
- (e) determining a clotting time of the patient
- 20 plasma and the PNP in each container using an activated thromboplastin time assay (APTT), wherein a patient plasma with a deficiency of Protein C or an increased inhibitor to Protein C activity has a decreased APTT compared to the APTT of PNP.

25

-9-

The method of Claim 8 wherein a Protein C activation accelerator is added to the plasmas in each container in step (b).

-10-

The method of Claim 8 wherein snake venom is admixed and plasmas in step (b) to accelerate the activation of Protein C to Protein Ca.

-35-

-11-

The method of Claim 10 wherein the snake venom is selected from Akistrodon Contortrix Contortrix venom and an active component thereof.

-12-

The method of Claim 8 wherein the TTP and calcium chloride as a reagent produces a selected standardizing prothrombin time (PT) in PNP of between about 10 and 13 seconds.

-13-

The method of Claim 12 wherein the time is about 11.6 seconds ± 0.5 second.

-14-

The method of Claim 13 wherein in the Akistrodon contortrix contortrix venom is admixed with the plasmas in step (b) to accelerate the activation of Protein C to Protein Ca.

-15-

The method of Claim 8 wherein in step (b) 30 parts by volume of PNP and patient plasma are separately mixed with 70 parts by volume each of Factor V and Factor VIII deficient plasma.

-16-

The method of Claim 15 wherein the APTT is determined by adding an APTT reagent to the plasmas in each container and then adding calcium chloride to clot the plasma in each container.

-36-

-17-

The method of Claim 16 wherein the APTT reagent produces a selected clotting time of between about 20 and 30 seconds in PNP with a mean range of about 26 seconds for greater than two thirds of the individuals with normal
5 plasma.

-18-

The method of Claim 8 wherein in addition a control plasma depleted of Protein C is tested along with the PNP and patient plasma.

-19-

The method of Claim 8 wherein in addition a control plasma with a known amount of Protein C is tested along with the PNP and patient plasma.

-20-

The method of Claim 8 wherein the TTP produces a selected standardized prothrombin time (PT) between about 10 and 13 seconds and wherein the TTP is used in step (b) in an amount between 20 and 50 microliters per milliliter
5 of patient plasma and PNP to generate thrombin without formation of fibrin.

-21-

The method of Claim 20 wherein the TTP is added in 10, 20, 30 and 50 milliliter amounts to separate containers of PNP and of patient plasma in step (b).

-22-

The method of Claim 8 wherein the time in step (d) is between about 0.5 and 24 hours.

-37-

-23-

The method of Claim 8 wherein a Protein C activator is provided in step (b) and wherein the time in step (d) is about 1.0 hour.

-24-

A kit for indirectly assaying for Protein C in blood plasma by a method which comprises providing in separate containers patient plasma and control pooled normal plasma (PNP); adding thrombomodulin/tissue factor (TTP) and calcium chloride to the plasmas in each container so as to activate Factor V to Factor Va and Factor VIII to Factor VIIIa protein C to activated protein C (Protein Ca) without fibrin formation in the plasmas; separately mixing Factor VIII and Factor V deficient plasma with the activated PNP and with the activated patient plasma in each of the containers; allowing time for Factor VIII and Factor V to be activated to Factor Va and Factor VIIIa and then to be inactivated by Protein Ca in the separate containers; and determining a clotting time of the patient plasma and the PNP in each container using an activated thromboplastin time assay (APTT), wherein a patient plasma with a deficiency of Protein C or with increased inhibitor activity against Protein Ca has a decreased APTT compared to the APTT of PNP which comprises:


(a) TTP with a standardized prothrombin time in PNP of between about 10 and 13 seconds to produce thrombin in a dosage amount of less than a dosage amount which produces fibrin formation in the PNP and the patient plasma;

(b) Factor V and Factor VIII and Protein C deficient plasmas; and

(c) an APTT reagent.

1 / 23


FIG. 1



- ▨ PT-BEFORE ACTIVATION
- ▩ PT-AFTER ACTIVATION
- PT-POST ACT., >5 MIN. INC

2/23

FIG. 2




▨ PT-BEFORE ACTIVATION

▧ PT-AFTER ACTIVATION

□ PT-POST ACTIVATION >5 MIN. INC.

3/23

FIG. 3



- PT-AFTER ACTIVATION
- PT-BEFORE ACTIVATION
- PT-POST ACTIVATION >5 MIN. INC.
- PT-500ng-BEFORE ACT.
- PT-500ng-AFTER ACT.
- PT-500ng-POST ACT. >5 MIN. INC.

4/23

FIG. 4A




FIG. 4B






FIG. 4C




5723

FIG. 5



6/23


FIG. 6



- PT-BEFORE ACTIVATION
- PT-AFTER ACTIVATION
- PT-POST ACTIVATION >5 MIN. INC.
- ▤ APTT-BEFORE ACTIVATION
- ▥ APTT-BEFORE ACTIVATION
- ▧ APTT-POST ACTIVATION >5 MIN. INC.


7/23

FIG. 7




8/23

FIG. 8




9/23

FIG. 9




10/23

FIG. 10




11/23

FIG. 11



12/23

FIG. 12



13/23

FIG. 13




FIG. 14





FIG. 15



16/23






FIG. 17




18/23

FIG. 18



19/23

FIG. 19



20/23

FIG. 20






FIG. 21




22/23

FIG. 22



23/23


FIG. 23



◆ FVIIIa INACTIVATED — FVIIIa LINE OF
BEST FIT

INTERNATIONAL SEARCH REPORT

International Application No PCT/US90/04349

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ³		
According to International Patent Classification (IPC) or to both National Classification and IPC		
IPC (5): C120 1/56; G01N 33/86 U.S. Cl. : 422/61 : 435/13 : 436/69,86		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁴		
Classification System	Classification Symbols	
U.S.	436/69,86; 422/61; 435/13	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁵		
III. DOCUMENTS CONSIDERED TO BE RELEVANT ^{1,4}		
Category ⁶	Citation of Document, ^{1,6} with indication, where appropriate, of the relevant passages ^{1,7}	Relevant to Claim No. ^{1,8}
Y	Chemical Abstracts, Vol. 105, Published 1986, Abstract No. 105:93300X, Martinoli et al, "Fast functional protein C assay using Protac, a novel protein C activator", see the entire document.	1-24
Y	EP, A, 0,260,707 (Matsumoto) 23 March 1988, See the entire document.	1-24
Y	US, A, 3,486,981 (Speck) 30 December 1969, see especially column 9.	1-24
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>[*] Special categories of cited documents: ^{1,3}</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application ^{1,9} cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other documents, such combination being obvious to a person skilled in the art.</p> <p>"Δ" document member of the same patent family</p> </div> </div>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search ²		Date of Mailing of this International Search Report ²
16 October 1990		20 DEC 1990
International Searching Authority ¹		Signature of Authorized Officer ¹⁰
ISA/US		 Robert J. Hill Jr.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.